surf break copy_edited.jpg
WM360_logo-18.png
surbreak-19.png
Search

Emerging Opportunities: Real-World Evidence

  • Key takeaways • Real-world evidence (RWE) has the potential to be useful across the entire healthcare ecosystem, including for clinical trials, care provision, determining treatment outcomes, and post-care safety monitoring. However, impact potential is relative to the quality and quantity of data available for analysis.

  • We have tracked 57 startups that we view as primarily focused on RWE business opportunities. Since 2019, these startups have raised $1.8 billion in VC and have an aggregate valuation of $16.0 billion (although valuations are not available for many of these companies).

  • We forecast the RWE solutions market to grow at a 15% CAGR from $1.1 billion in 2020 to $2.9 billion in 2027.

  • Key startups opportunities include building proprietary datasets, developing real-world data (RWD) analytical tools, and creating data standardization and management solutions.


CONTINUE READING

Recent Posts

See All

Invitae to Acquire Ciitizens

Invitae (NYSE: NVTA), a leading medical genetics company, today announced it has entered into a definitive agreement to acquire Ciitizen, a patient-centric consumer health tech company. Backed by a16z